Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group.
V Joly, M Moroni, E Concia, A Lazzarin, B Hirschel, J Jost, F Chiodo, Z Bentwich, WC Love, DA Hawkins, EG Wilkins, AJ Gatell, N Vetter, C Greenwald, WW Freimuth, W de Cian
Antimicrobial Agents and Chemotherapy | Published : 2000
We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.